In this webinar, Evidera experts present guidance on why strong connections with registry groups and stakeholder populations are important for generating relevant real-world evidence to advance treatments.
Standard models in evidence synthesis work well in settings characterized by a large evidence base, the absence of effect modifiers, and connected networks. Handling sparse data, substantial between-study heterogeneity and disconnected studies, however, poses challenges to researchers and requires advanced methodology.
IQVIA’s Mui Van Zandt, BMIS and Raina Olexa, MS lead a conversation on embracing FDA’s guidance on the use of RWD, and how your organization can navigate data quality, curation, and management challenges for better research.
Experts expand on the need for a comprehensive understanding of all sources of data in DCTs, and the need to evaluate those data centrally in real time to mitigate the risks associated with their capture (including data capture at the edge of the network (wearables)).